Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 14/20 | 0.36 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085731 | 0.80 | NFE2L2 (0.40) | NFE2L2PLCG1TRIM24TRIM33ALDH1A1 | |
| SCHEMBL2083969 | 0.80 | P2RX7 (0.35) | NFE2L2PLCG1NPC1 | |
| SCHEMBL80776 | 0.75 | TRIM24 (0.38) | NFE2L2PLCG1TRIM24TRIM33TDP1 | |
| SCHEMBL2084210 | 0.75 | ALDH1A1 (0.46) | PLCG1NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL586118 | 0.72 | NFE2L2 (0.48) | NFE2L2TRIM24TRIM33LMNA | |
| SCHEMBL6115316 | 0.70 | TRIM24 (0.39) | TRIM24TRIM33NPC1RAB9AALDH1A1 | |
| SCHEMBL934218 | 0.69 | GRM5 (0.45) | NFE2L2ALDH1A1LMNA | |
| SCHEMBL4229224 | 0.69 | HTT (0.45) | NFE2L2TRIM24TRIM33TDP1NPC1 | |
| SCHEMBL22212665 | 0.69 | NFE2L2 (0.39) | NFE2L2TRIM24TRIM33NPC1RAB9A | |
| SCHEMBL2084716 | 0.69 | KDM4E (0.37) | NFE2L2TRIM24TRIM33ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | disclosed |
| US-7291631-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | NFE2L2 1677/4885PLCG1 4241/4885TRIM24 3247/4885 |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | NFE2L2 1764/4885PLCG1 4208/4885TRIM24 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.